Loading...
XSHE000597
Market cap976mUSD
Jan 14, Last price  
5.08CNY
1D
3.25%
1Q
11.40%
Jan 2017
12.78%
Name

Northeast Pharmaceutical Group Co

Chart & Performance

D1W1MN
XSHE:000597 chart
P/E
19.98
P/S
0.87
EPS
0.25
Div Yield, %
3.07%
Shrs. gr., 5y
3.42%
Rev. gr., 5y
2.00%
Revenues
8.24b
-6.42%
1,619,687,4461,833,077,1501,918,238,4113,706,074,4854,609,773,1785,093,588,3024,828,745,9963,882,779,5913,864,913,0993,870,591,2274,333,321,6433,834,432,0304,814,401,6595,676,351,5547,466,555,2378,220,102,8987,384,354,3758,145,117,4568,808,942,6288,243,175,021
Net income
358m
+2.34%
8,128,79413,351,36819,625,81147,521,489357,906,459476,079,38150,011,33508,103,657087,075,016023,788,059118,995,323195,199,719173,978,08712,256,82599,027,108350,252,859358,458,434
CFO
587m
-47.07%
211,058,827111,402,7770198,560,972709,025,038615,905,583255,962,765086,090,004046,990,98399,700,460384,514,5530285,090,647352,599,584570,918,423746,506,4831,108,571,233586,751,744
Dividend
May 23, 20240.1 CNY/sh
Earnings
Apr 18, 2025

Profile

Northeast Pharmaceutical Group Co., Ltd. provides chemical synthetic and bio-fermentation APIs, and medicinal and micro-ecological preparation products in China. It offers various nutritional products, such as Vitamin C, L-Carnitine, and other products; API products comprising fosfomycin, anti-aids, and other products; and chemical products, including chemical and pharmaceutical intermediates, chiral separation reagent products, etc. The company also provides digestives, narcotic medicines, cardiovascular, cerebrovascular medicines, etc. In addition, it engages in medical distribution business. Northeast Pharmaceutical Group Co., Ltd. was founded in 1993 and is based in Shenyang, China.
URL
https://www.nepharm.com.cn/
IPO date
May 23, 1996
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
8,243,175
-6.42%
8,808,943
8.15%
Cost of revenue
7,800,850
7,856,611
Unusual Expense (Income)
NOPBT
442,325
952,331
NOPBT Margin
5.37%
10.81%
Operating Taxes
112,194
168,393
Tax Rate
25.36%
17.68%
NOPAT
330,132
783,939
Net income
358,458
2.34%
350,253
253.69%
Dividends
(219,775)
(18,870)
Dividend yield
2.88%
0.22%
Proceeds from repurchase of equity
(14,216)
BB yield
0.19%
Debt
Debt current
1,978,430
1,976,784
Long-term debt
212,574
273,878
Deferred revenue
157,119
174,717
Other long-term liabilities
359,919
238,000
Net debt
(3,460,179)
(1,594,237)
Cash flow
Cash from operating activities
586,752
1,108,571
CAPEX
(235,432)
Cash from investing activities
(227,965)
(256,341)
Cash from financing activities
381,099
FCF
671,460
1,157,814
Balance
Cash
5,651,183
3,844,899
Long term investments
2
1
Excess cash
5,239,024
3,404,452
Stockholders' equity
2,621,342
2,690,351
Invested Capital
5,057,036
4,512,768
ROIC
6.90%
14.99%
ROCE
5.76%
13.21%
EV
Common stock shares outstanding
1,433,834
1,347,873
Price
5.33
-15.53%
6.31
1.45%
Market cap
7,642,334
-10.14%
8,505,080
1.45%
EV
4,352,627
7,064,790
EBITDA
1,017,133
1,513,437
EV/EBITDA
4.28
4.67
Interest
133,215
92,114
Interest/NOPBT
30.12%
9.67%